LIFECORE BIOMEDICAL, INC. Finance Lease, Right-of-Use Asset, Amortization
LIFECORE BIOMEDICAL, INC. (LFCR) reported Finance Lease, Right-of-Use Asset, Amortization of $79.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $39.00K.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $40.00K.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $40.00K.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-05-25 was $39.00K, a 8.33% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $160.00K, a 16.79% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $137.00K, a 15.13% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $119.00K, a 19.00% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $100.00K, a 14.53% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 7 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $79.00K 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $40.00K 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | $93.00K 10-KT · filed 2026-03-16 | |||||
| 2025-09-30 | $40.00K 10-Q · filed 2025-11-06 | |||||
| 2025-05-25 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $79.00K 10-Q · filed 2026-08-05 | $160.00K 10-KT · filed 2026-03-16 | |||
| 2025-02-23 | $40.00K 10-Q · filed 2026-05-06 | $120.00K 10-Q · filed 2025-04-03 | ||||
| 2024-08-25 | $36.00K 10-Q · filed 2025-11-06 | $72.00K derived: sum of 2 quarters · filed 2026-03-16 | ||||
| 2024-05-26 | $36.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $137.00K 10-KT · filed 2026-03-16 | ||||
| 2024-02-25 | $101.00K 10-Q · filed 2025-04-03 | |||||
| 2023-05-28 | $119.00K 10-K · filed 2024-08-26 | |||||
| 2022-05-29 | $100.00K 10-K · filed 2024-08-26 | $113.00K 10-K · filed 2022-09-14 | ||||
| 2021-05-30 | $117.00K 10-K/A · filed 2023-03-16 | |||||
| 2020-05-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $59.00K derived: sum of 2 quarters · filed 2021-07-29 | $88.00K derived: sum of 3 quarters · filed 2021-07-29 | $116.00K 10-K · filed 2021-07-29 | ||
| 2020-02-23 | $29.00K 10-Q · filed 2020-04-03 | $58.00K derived: sum of 2 quarters · filed 2020-04-03 | $86.00K 10-Q · filed 2020-04-03 | |||
| 2019-11-24 | $29.00K 10-Q · filed 2020-01-02 | $57.00K 10-Q · filed 2020-01-02 | ||||
| 2019-08-25 | $28.00K 10-Q · filed 2019-10-03 | |||||
| 2019-05-26 | $100.00K 10-K · filed 2021-07-29 | |||||
| 2018-05-27 | $100.00K 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |